Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis (Q24198024)

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Clinical trial: Effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Different therapy for different types of ulcerative colitis in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

The value of 5-aminosalicylic acid in inflammatory bowel disease for patients intolerant or allergic to sulphasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: randomized, placebo-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Distal ulcerative colitis refractory to rectal mesalamine: role of transdermal nicotine versus oral mesalamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

The effect of mesalazine therapy on quality of life in patients with mildly and moderately active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Trial of trefoil factor 3 enemas, in combination with oral 5-aminosalicylic acid, for the treatment of mild-to-moderate left-sided ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Quality of life improvements attributed to combination therapy with oral and topical mesalazine in mild-to-moderately active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Randomised clinical trial: early assessment after 2 weeks of high-dose mesalazine for moderately active ulcerative colitis - new light on a familiar question

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

A new oral delivery system for 5-ASA: preliminary clinical findings for MMx.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: results of a randomized, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Mesalazine tolerance in patients with inflammatory bowel disease and previous intolerance or allergy to sulphasalazine or sulphonamides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine alone in ulcerative colitis: randomized, double-blind, placebo-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Interstitial nephritis from mesalazine: case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

An experiment to determine the active therapeutic moiety of sulphasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

An oral preparation to release drugs in the human colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Predictors of medication adherence in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Sulphasalazine in ulcerative colitis: in memoriam?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Systematic review: adherence issues in the treatment of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Kinetics of 5-aminosalicylic acid after jejunal instillation in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Sulphasalazine induced seminal abnormalities in ulcerative colitis: results of mesalazine substitution

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Cortisone in ulcerative colitis; final report on a therapeutic trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Cortisone and corticotrophin in ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Renal impairment in patients with inflammatory bowel disease: association with aminosalicylate therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

Absorption, metabolism, and excretion of salicylazosulfapyridine in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

7 January 2021

Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

7 January 2021

Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

7 January 2021

Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

7 January 2021

High-dose mesalazine treatment for ulcerative colitis patients who relapse under low-dose maintenance therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

7 January 2021

Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

7 January 2021

Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

7 January 2021

Once-daily, high-concentration MMX mesalamine in active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

7 January 2021

[Successful acute treatment of chronic inflammatory intestinal diseases with oral 5-aminosalicylic acid]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

7 January 2021

Therapeutic Efficacy of Sulfasalazine and Its Metabolites in Patients with Ulcerative Colitis and Crohn's Disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

7 January 2021

Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

7 January 2021

Experience with Eudragit-S-coated mesalamine (Asacol) in inflammatory bowel disease. An open study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

7 January 2021

Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

7 January 2021

Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

7 January 2021

Review article: the mode of action of the aminosalicylates in inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

7 January 2021

Mesalamine capsules enhance the quality of life for patients with ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

7 January 2021

Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

7 January 2021

Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

7 January 2021

Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

7 January 2021

Increasing patient adherence to gastroenterology treatment and prevention regimens

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

7 January 2021

Olsalazine in active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

7 January 2021

Acute interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

7 January 2021

Prospective, randomized, double-blind comparison of benzalazine and sulfasalazine in the treatment of active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

7 January 2021

Interstitial nephritis after treatment with mesalazine in the patient with ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

7 January 2021

Olsalazine in patients intolerant of sulphasalazine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

7 January 2021

Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

7 January 2021

Olsalazine in the treatment of ulcerative colitis among patients intolerant of sulphasalazine: a prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

7 January 2021

Treatment of ulcerative colitis with olsalazine and sulphasalazine: efficacy and side-effects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

7 January 2021

Effects of mesalazine substitution on salicylazosulfapyridine-induced seminal abnormalities in men with ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

7 January 2021

Pentasa in lieu of sulfasalazine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

7 January 2021

Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB3

7 January 2021

10.1002/14651858.CD000543.PUB3

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

477602

477602

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference